- Home
- SPRB
as 04-24-2025 3:43pm EST
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 5.5M | IPO Year: | 2020 |
| Target Price: | $1.75 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.12 - $0.87 | Next Earning Date: | 04-15-2025 |
| Revenue: | $4,911,000 | Revenue Growth: | -51.32% |
| Revenue Growth (this year): | -58.46% | Revenue Growth (next year): | 312.50% |
Latest Spruce Biosciences Inc. News
SPRB Breaking Stock News: Dive into SPRB Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin
Business Wire
10 days ago
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Zacks
a month ago
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
Zacks
4 months ago
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
MT Newswires
4 months ago
JMP Securities Downgrades Spruce Biosciences to Market Perform From Market Outperform
Benzinga
4 months ago
Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder
Business Wire
4 months ago
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Simply Wall St.
5 months ago
Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Compare SPRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRB Spruce Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.